Dipeptides

Worldwide L-Carnosine Industry to 2025 - Featuring Holstein, Suzhou Fushilai & Wuhan Jetide Among Others

Retrieved on: 
Wednesday, September 2, 2020

This report is a professional and in-depth study on the current state of the global L-Carnosine market with a focus on the Chinese market.

Key Points: 
  • This report is a professional and in-depth study on the current state of the global L-Carnosine market with a focus on the Chinese market.
  • Key points of L-Carnosine Market Report:
    The report provides a basic overview of L-Carnosine industry including: definition, applications and manufacturing technology.
  • The global L-Carnosine market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  • The report then estimates 2020-2025 development trends, analyse upstream raw materials, downstream demand, and current market dynamics of L-Carnosine market.

L-Carnosine Market Insights (2020 to 2025) - Analysis and Forecast for the Global and Chinese Markets - ResearchAndMarkets.com

Retrieved on: 
Monday, August 31, 2020

The report explores Global and Chinese major players in L-Carnosine market.

Key Points: 
  • The report explores Global and Chinese major players in L-Carnosine market.
  • The report depicts the global and Chinese total L-Carnosine market including: capacity, production, production value, cost/profit, supply/demand and Chinese import/export, by statistical analysis.
  • The global L-Carnosine market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  • Overall, the report provides an in-depth insight of 2015-2025 global and Chinese L-Carnosine market covering all important parameters.

FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

Retrieved on: 
Saturday, August 29, 2020

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation.

Key Points: 
  • The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of the contact person above, on August 29, 2020 at 10.00 (CET).
  • Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
  • Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.

FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

Retrieved on: 
Saturday, August 29, 2020

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation.

Key Points: 
  • The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of the contact person above, on August 29, 2020 at 10.00 (CET).
  • Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
  • Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.

Medtronic Resolute Onyx™ DES Receives First and Only One-Month DAPT Indication for High Bleeding Risk Patients in Europe

Retrieved on: 
Friday, June 5, 2020

Resolute Onyx DES is not currently indicated for HBR patients with one-month DAPT in the United States.Data have been submitted to the FDA with the intent of obtaining a one-month DAPT US Indication for Resolute Onyx DES.

Key Points: 
  • Resolute Onyx DES is not currently indicated for HBR patients with one-month DAPT in the United States.Data have been submitted to the FDA with the intent of obtaining a one-month DAPT US Indication for Resolute Onyx DES.
  • Through the Onyx ONE Global Clinical Program, we have observed that Resolute Onyx DES with one-month of DAPT in these complex patients is safe and effective.
  • This indication will further substantiate the option for shorter DAPT regimens, if individual patient needs demand it.
  • The indication is based on results from the Onyx ONE Global Study, the first prospective, randomized, one-month DAPT trial comparing Resolute Onyx to a competitive DES (BioFreedom DCS) in nearly 2,000 HBR patients.

Sale of Bionomics’ French Subsidiaries to Domain Therapeutics

Retrieved on: 
Wednesday, December 11, 2019

The sale price of 1,810,028.97 is the amount of intercompany debt owed by Bionomics to the subsidiaries for the scientific research conducted by them on Bionomics drug candidates and this debt will be assumed by Domain upon acquisition of the Companies.

Key Points: 
  • The sale price of 1,810,028.97 is the amount of intercompany debt owed by Bionomics to the subsidiaries for the scientific research conducted by them on Bionomics drug candidates and this debt will be assumed by Domain upon acquisition of the Companies.
  • We are pleased with the outcome of the sale of our French subsidiaries which is part of our ongoing cost reduction process, consolidation of our operations in Adelaide and focus on the clinical development of BNC210 for post-traumatic stress disorder, said Dr. Errol De Souza, Executive Chairman of Bionomics.
  • The offer from Domain is subject to satisfaction of a number of conditions precedent, including entering into definitive contractual documentation satisfactory to both parties and regulatory approval.
  • Bionomics lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (7) nicotinic acetylcholine receptor.

Resolute Onyx™ DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk (HBR) Patients with One-Month DAPT

Retrieved on: 
Thursday, September 26, 2019

This study provides important advances in evidence for physicians determining the optimal duration of DAPT following PCI among high bleeding risk patients.

Key Points: 
  • This study provides important advances in evidence for physicians determining the optimal duration of DAPT following PCI among high bleeding risk patients.
  • In addition to meeting the primary endpoint, the study showed superior acute performance2for Resolute Onyx versus BioFreedom, with superior device success of 92.8% versus 89.7%, respectively [p=0.007].
  • At one year, there was low (2.8%) target lesion revascularization (TLR) for Resolute Onyx versus 4.0% for the comparator stent.
  • The Onyx ONE Global Study and Onyx ONE Clear Study make up the Medtronic Onyx ONE Month DAPT Program that has enrolled approximately 2,700 patients at up to 140 sites worldwide.

Oncopeptides Will Host a Webcast on Monday, 17 June at 09:00 (CET) to Review and Update Presentations From European Hematology (EHA) Meeting

Retrieved on: 
Thursday, June 13, 2019

This information was submitted for publication at 09:00 CET, 13 June 2019

Key Points: 
  • This information was submitted for publication at 09:00 CET, 13 June 2019
    Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers.
  • The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC).
  • Melflufen is in development as a new treatment for the hematological cancer multiple myeloma, including the Phase 2 pivotal trial HORIZON currently underway and a global confirmatory Phase 3 trial (OCEAN) continuing enrollment.
  • Oncopeptides' headquarters is located in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

Oncopeptides Will Host a Webcast on Monday, 17 June at 09:00 (CET) to Review and Update Presentations From European Hematology (EHA) Meeting

Retrieved on: 
Thursday, June 13, 2019

This information was submitted for publication at 09:00 CET, 13 June 2019

Key Points: 
  • This information was submitted for publication at 09:00 CET, 13 June 2019
    Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers.
  • The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC).
  • Melflufen is in development as a new treatment for the hematological cancer multiple myeloma, including the Phase 2 pivotal trial HORIZON currently underway and a global confirmatory Phase 3 trial (OCEAN) continuing enrollment.
  • Oncopeptides' headquarters is located in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting

Retrieved on: 
Monday, June 3, 2019

The data demonstrate that melflufen may offer positive disease stabilization and favorable time to next treatment (TTNT) outcomes in heavily-pretreated patients with relapsed/refractory multiple myeloma (RRMM).

Key Points: 
  • The data demonstrate that melflufen may offer positive disease stabilization and favorable time to next treatment (TTNT) outcomes in heavily-pretreated patients with relapsed/refractory multiple myeloma (RRMM).
  • Results support those of previous data showing the promising efficacy profile of melflufen for the treatment of RRMM.
  • "In addition to the data presented at ASCO, data from the melflufen clinical programs have also been selected for four presentations at the 2019 EHA Annual Congress, including updated data from the HORIZON Phase 2 pivotal clinical trial that will serve as the foundation for our NDA submission."
  • Melflufen is in development as a new treatment for the hematological cancer multiple myeloma, including the Phase 2 pivotal trial HORIZON currently underway and a global confirmatory Phase 3 trial (OCEAN) continuing enrollment.